chemopreventive role of curcumin and resveratrol | kalyanipharmaceuticals

“ xmlns:fb='http://www.facebook.com/2008/fbml' ” chemopreventive role of curcumin and resveratrol | kalyanipharmaceuticals

Thursday, October 7, 2010

chemopreventive role of curcumin and resveratrol

Fav This With Technorati

Add To Del.icio.us

Add To Facebook

Colorectal cancer (CRC) is a second leading cause of cancer deaths in the Western world. Currently there is no effective treatment except resection at a very early stage with or without chemotherapy. Of various epithelial cancers, CRC in particular has a potential for prevention, since most cancers follow the adenoma-carcinoma sequence, and the interval between detection of an adenoma and its progression to carcinoma is usually about a decade. However no effective chemopreventive agent except COX-2 inhibitors, limited in their scope due to cardiovascular side effects, have shown promise in reducing adenoma recurrence. To this end, natural agents that can target important carcinogenic pathways without demonstrating discernible adverse effects would serve as ideal chemoprevention agents. In this review, we discuss merits of two such naturally occurring dietary agents-curcumin and resveratrol-for chemoprevention of CRC

Colorectal cancer (CRC) is a second leading cause of cancer deaths in the Western world. Currently there is no effective treatment except resection at a very early stage with or without chemotherapy. Of various epithelial cancers, CRC in particular has a potential for prevention, since most cancers follow the adenoma-carcinoma sequence, and the interval between detection of an adenoma and its progression to carcinoma is usually about a decade. However no effective chemopreventive agent except COX-2 inhibitors, limited in their scope due to cardiovascular side effects, have shown promise in reducing adenoma recurrence. To this end, natural agents that can target important carcinogenic pathways without demonstrating discernible adverse effects would serve as ideal chemoprevention agents. In this review, we discuss merits of two such naturally occurring dietary agents-curcumin and resveratrol-for chemoprevention of CRC

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Featured Content Slider

Max Payne Game

Max Payne is a BAFTA award winning[1] third-person shooter video game developed by Finnish Remedy Entertainment, produced by 3D Realms and published by Gathering of Developers in July 2001 for Windows. Ports later in the year for the Xbox, PlayStation 2 and the GameBoy Advance were published by Rockstar Games. A Macintosh port was published in July 2002 by MacSoft in[...]
Mabthera

Rituximab destroys both normal and malignant [[B cells]] that have CD20 on their surfaces, and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells. ===Hematological neoplastic diseases=== Rituximab is frequently used to treat [[Hematological malignancy|hematological neoplasms]] such as [[leukemia]]s and [[lymphoma]]s. In [[multiple myeloma]], treatment with rituximab fails to deplete circulating CD20+ B or plasma cells, even after up to four cycles of treatment; in some patients, rituximab treatment increases the number of circulating CD20+ B cells. [http://www.doaj.org/doaj?func=abstract&id=260717&recNo=32&toc=1/ Multiple myeloma includes CD20+ B and plasma cells that persist in patients treated with rituximab. LM Pilarski, E Baigorri, MJ Mant, PM Pilarski, P Adamson, H Zola, AR Belch. Clinical Medicine:Oncology, 2:275-281, 2008] ===Autoimmune diseases=== Rituximab has been shown to be an effective [[rheumatoid arthritis]] treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.{{cite journal | author = Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T | title = Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | journal = N Engl J Med | volume = 350 | issue = 25 | pages = 2572–81 | year = 2004 | pmid = 15201414 | doi = 10.1056/NEJMoa032534}} In the United States, it has been FDA-approved for use in combination with [[methotrexate]] (MTX) for reducing signs and symptoms in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-[[TNF-alpha]] therapies. [...]
Avastin

Colorectal Cancer Lymphoma Breast Cancer Oncology [...]
Herceptin

Colorectal Cancer Breast Cancer Organ Rejection [...]
Transformer Movie
Transformers is a 2007 live-action-thriller film adaptation of the Transformers franchise, directed by Michael Bay and written by John Rogers, Roberto Orci and Alex Kurtzman. It stars Shia LaBeouf as Sam Witwicky, a teenager involved in a war between the heroic Autobots and the evil Decepticons, two factions of alien robots who can disguise themselves by transforming into everyday machinery. The Decepticons desire control of the All Spark, the object that created their robotic race, with the intention of using it to build [...]
Max Payne Game

Max Payne is a BAFTA award winning[1] third-person shooter video game developed by Finnish Remedy Entertainment, produced by 3D Realms and published by Gathering of Developers in July 2001 for Windows. Ports later in the year for the Xbox, PlayStation 2 and the GameBoy Advance were published by Rockstar Games. A Macintosh port was published in July 2002 by MacSoft in[...]
Mabthera

Rituximab destroys both normal and malignant [[B cells]] that have CD20 on their surfaces, and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells. ===Hematological neoplastic diseases=== Rituximab is frequently used to treat [[Hematological malignancy|hematological neoplasms]] such as [[leukemia]]s and [[lymphoma]]s. In [[multiple myeloma]], treatment with rituximab fails to deplete circulating CD20+ B or plasma cells, even after up to four cycles of treatment; in some patients, rituximab treatment increases the number of circulating CD20+ B cells. [http://www.doaj.org/doaj?func=abstract&id=260717&recNo=32&toc=1/ Multiple myeloma includes CD20+ B and plasma cells that persist in patients treated with rituximab. LM Pilarski, E Baigorri, MJ Mant, PM Pilarski, P Adamson, H Zola, AR Belch. Clinical Medicine:Oncology, 2:275-281, 2008] ===Autoimmune diseases=== Rituximab has been shown to be an effective [[rheumatoid arthritis]] treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.{{cite journal | author = Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T | title = Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | journal = N Engl J Med | volume = 350 | issue = 25 | pages = 2572–81 | year = 2004 | pmid = 15201414 | doi = 10.1056/NEJMoa032534}} In the United States, it has been FDA-approved for use in combination with [[methotrexate]] (MTX) for reducing signs and symptoms in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-[[TNF-alpha]] therapies. [...]

Connect with Facebook